63 results
8-K
EX-99.2
TXMD
TherapeuticsMD Inc
5 Dec 22
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
7:31am
upon achieving certain annual net sales targets (cumulative milestones $30mm) Downside protection of ~$42.6mm from minimum annual royalties
SC 14D9
2xn83um8 8a
10 Jun 22
Tender offer solicitation
6:51pm
SC TO-T
EX-99
x4cd6tpm6iwr0 ef218f
6 Jun 22
Third party tender offer statement
5:02pm
8-K
EX-99.2
78jb5d wg66
16 May 22
TherapeuticsMD Announces First Quarter 2022 Financial Results
4:09pm
8-K
EX-99.2
25c94n
10 Mar 22
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
7:15am
8-K/A
EX-99.1
d98d6pk24l0sigsv4fa
16 Nov 21
Results of Operations and Financial Condition
6:30am
8-K
EX-99.2
l70lhtck lt
4 Aug 21
TherapeuticsMD Announces Second Quarter 2021 Financial Results
7:00am
8-K
EX-99.2
327 7z8o9j
6 May 21
TherapeuticsMD Announces First Quarter 2021 Financial Results
7:00am